Discovery of potential ovarian cancer biomarkers using low molecular weight blood plasma proteome profiling by mass spectrometry
https://doi.org/10.17650/1994-4098-2013-0-3-4-90-96
Abstract
At present, there is no screening test for the early detecting and monitoring of ovarian cancer, one of the most lethal form of gynaecological malig- nancy in the worldwide. In this study, the new methodology for the search of tumor markers of ovarian cancer, involving profiling the low-molec- ular blood plasma proteomes, is developed, unified and approved. The given approach included three basic components: pre-preparation of samples, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and bioinformatics software for mass spectral data process- ing. Opportunities and prospects of the developed approach for the detection of potential ovarian cancer markers were shown. For search of po- tential tumor markers, screening of 40 blood plasma samples from ovarian cancer patients and 48 control samples were carried out. As a result of the present research, peptides/polypeptides which can be used in future for detecting this pathology were found out.
About the Authors
V. E. Shevchenko
Oncoproteomics Laboratory, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
N. E. Arnotskaya
Oncoproteomics Laboratory, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
E. V. Ogorodnikova
Blood Transfusion Department, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
N. R. Pogosyan
Gynecology Department, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. N. Gritsay
Gynecology Department, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
K. I. Zhordania
Gynecology Department, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Permuth-Wey J., Sellers T.A. Epidemiology of ovarian cancer. Methods Mol Biol 2009;472:413–37.
2. Шевченко В.Е., Арноцкая Н.Е., Макаров Д.Е. и др. Протеомика в диагностике рака яичников. Опухоли женской репродуктивной системы 2011;(2):56–64.
3. Rai A.J., Zhang Z., Rosenzweig J. et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002;126(12):1518–26.
4. Tung C.S., Wong K.K., Mok S.C. Biomarker discovery in ovarian cancer. Womens Health (Lond Engl) 2008;4:27–40.
5. Jackson D., Craven R.A., Hutson R.C. et al. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 2007;13(24):7370–9.
6. Шевченко В.Е. Современные масс-спектрометрические методы в ранней диагностике рака. Масс-спектрометрия 2004;1(2):103–26.
7. Etzioni R., Urban N., Ramsey S. et al. The case for early detection. Nat Rev Cancer 2003;3(4):243–52.
8. Aldred S., Grant M.M., Griffiths H.R. The use of proteomics for the assessment of clinical samples in research. Clin Biochem 2004;37(11):943–52.
9. Banks R.E., Dunn M.J., Hochstrasser D.F. et al. Proteomics: new perspectives, new biomedical opportunities. Lancet 2000;356(9243):1749–56.
10. Diamandis E.P. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002;360(9327):170.
11. Guillaume E., Zimmermann C., Burkhard P.R. et al. A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2003;3(8):1495–9.
12. Howard B.A., Wang M.Z., Campa M.J. et al. Identification and validation of a potential lung cancer serum biomarker detected by matrix- assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 2003;3(9):1720–4.
13. Koopmann J., Zhang Z., White N. et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10(3):860–8.
14. Menon U., Jacobs I. Screening for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002;16(4):469–82.
15. Petricoin E.F., Ardekani A.M., Hitt B.A. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359(9306):572–7.
16. Zheng P.P., Luider T.M., Pieters R. et al. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 2003;62(8):855–62. 17. Whiteley G.R., Colantonio S., Sacconi A., Saul R.G. Analytical considerations for mass spectrometry profiling in serum biomarker discovery. Clin Lab Med 2009;29(1):57–69.
17. Baggerly K.A., Morris J.S., Edmonson S.R., Coombes K.R. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97(4):307–9.
18. Kristina G., Radomir P., Eva B. et al. When one chip is not enough: augmenting the validity of SELDI-TOF proteomic profiles of clinical specimens. Lab Chip 2009;9(7):1014–17.
19. Шевченко В.Е., Арноцкая Н.Е., Трифонова О.П. и др. Профилирование низкомолекулярного протеома плазмы крови для обнаружения потенциальных маркеров рака легкого. Масс-спектроме- трия 2007;4(4):245–54.
20. Shevchenko V.E., Arnotskaya N.E., Zaridze D.G. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry. Eur J Mass Spectrom (Chichester, Eng) 2010;16(4):539–49.
21. Пятницкий М.А., Лисица А.В., Шевченко В.Е. и др. Выявление дифференциальных признаков плоскоклеточного рака легкого с помощью масс-спектрометрического профилирования плазмы крови. Масс-спектрометрия 2011;8(2):99–105.
22. Villanueva J., Shaffer D.R., Philip J. et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns.J Clin Invest 2006;116(1):271–84.
23. Ketterlinus R., Hsieh S.Y., Teng S.H. et al. Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. Biotechniques 2005;(Suppl):37–40.
24. Сорокина А.В., Радзинский В.Е., Мус- тафина Е.А. и др. Масс-спектрометрия – новый подход в диагностике аденомиоза и рака тела матки. Опухоли женской репродуктивной системы 2011;(2):65–72.
25. Шевченко В.Е., Мадина Х., Поддубная И.В. и др. Массспектрометрическое профилирование низкомолекулярного протеома плазмы крови для обнаружения потенциальных маркеров рака молочной железы. Вестн РОНЦ 2011;22(3):27–33.
26. Zhou M., Lucas D.A., Chan K.C. et al. An investigation into the human serum «interactome». Electrophoresis 2004;25(9):1289–98.
27. Callesen A.K., Mogensen O., Jensen A.K. et al. Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: A systematic review. J Proteomics 2012;75(10):2758–72.
28. Fiedler G.M., Baumann S., Leichtle A. et al. Standardized peptidome profiling of human urine by magnetic bead separation and matrix- assisted laser desorption/ionization time-of- flight mass spectrometry. Clin Chem 2007;53(3):421–8.
29. Schaub N.P., Jones K.J., Nyalwidhe J.O. et al. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg 2009;208(5):970–8.
30. Schwamborn K., Krieg R.C., Grosse J. et al. Serum proteomic profiling in patients with bladder cancer. Eur Urol 2009;56(6):989–96.
Review
For citations:
Shevchenko V.E., Arnotskaya N.E., Ogorodnikova E.V., Pogosyan N.R., Gritsay A.N., Zhordania K.I. Discovery of potential ovarian cancer biomarkers using low molecular weight blood plasma proteome profiling by mass spectrometry. Tumors of female reproductive system. 2013;(3-4):90-96. (In Russ.) https://doi.org/10.17650/1994-4098-2013-0-3-4-90-96
Views:
469
Email this article 